Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 5/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | BAX | Q07812 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928697 | 0.81 | ELANE (0.42) | ESR1MEN1KMT2AESR2ELANE | |
| SCHEMBL928695 | 0.81 | ELANE (0.42) | ESR1MEN1KMT2AESR2ELANE | |
| SCHEMBL28171294 | 0.80 | AKR1C3 (0.48) | KMT2AELANEMAPTHPGD | |
| SCHEMBL20348446 | 0.79 | CYP19A1 (0.41) | KMT2AELANEPARP10MAPT | |
| SCHEMBL927846 | 0.77 | CYP3A4 (0.55) | ESR1MEN1KMT2AESR2 | |
| SCHEMBL181396 | 0.76 | MEN1 (0.61) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL8924644 | 0.74 | ESR1 (0.64) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL2581335 | 0.72 | AKR1C3 (0.38) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL219559 | 0.72 | AKR1C3 (0.38) | ESR1MEN1KMT2AESR2LTA4H | |
| Mequinol SCHEMBL3120838 | 0.70 | ESR2 (0.53) | MEN1KMT2AESR2LTA4HMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222446-B2 | Method for producing dihydroxybenzene derivative | MITSUI CHEMICALS, INC. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110004013-A1 | METHOD FOR PRODUCING DIHYDROXYBENZENE DERIVATIVE | MITSUI CHEMICALS, INC. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2269976-A1 | PROCESS FOR PRODUCING DIHYDROXYBENZENE DERIVATIVE | Mitsui Chemicals, Inc. (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110004013-A1 | METHOD FOR PRODUCING DIHYDROXYBENZENE DERIVATIVE | UBE2B, UBE2G2, TUBB2B | ESR1 742/4885MEN1 4103/4885KMT2A 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.